|
| 產地 | 進口、國產 |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號 | CS11031 |
| 應用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號 | |
| 抗體名 | Anti-RAG2 |
| 克隆性 | |
| 靶點 | 詳見說明書 |
| 適應物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標識物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthetic peptide derived from human RMND1 |
中文名稱 重組激活基因2蛋白抗體品牌
英文名稱 Anti-RAG2
別 名 RAG 2; RAG-2; RAG2; RAG2_HUMAN; Recombination activating gene 2; V(D)J recombination activating protein 2; V(D)J recombination-activating protein 2.
產品屬性：
重組激活基因2蛋白抗體品牌 濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應 Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep
產品類型 一抗
研究領域 細胞生物 免疫學 表觀遺傳學
蛋白分子量 predicted molecular weight: 58kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human RAG2
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
重組激活基因2蛋白抗體品牌 產品應用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產品介紹 Catalytic component of the RAG complex, a multiprotein complex that mediates the DNA cleavage phase during V(D)J recombination. V(D)J recombination assembles a diverse repertoire of immunoglobulin and T-cell receptor genes in developing B and T lymphocytes through rearrangement of different V (variable), in some cases D (diversity), and J (joining) gene segments. In the RAG complex, RAG1 mediates the DNA-binding to the conserved recombination signal sequences (RSS) and catalyzes the DNA cleavage activities by introducing a double-strand break between the RSS and the adjacent coding segment. RAG2 is not a catalytic component but is required for all known catalytic activities. DNA cleavage occurs in 2 steps: a first nick is introduced in the top strand immediately upstream of the heptamer, generating a 3'-hydroxyl group that can attack the phosphodiester bond on the opposite strand in a direct transesterification reaction, thereby creating 4 DNA ends: 2 hairpin coding ends and 2 blunt, 5'-phosphorylated ends. The chromatin structure plays an essential role in the V(D)J recombination reactions and the presence of histone H3 trimethylated at 'Lys-4' (H3K4me3) stimulates both the nicking and haipinning steps. The RAG complex also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B lymphocytes. The introduction of DNA breaks by the RAG complex on one immunoglobulin allele induces ATM-dependent repositioning of the other allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. In addition to its endonuclease activity, RAG1 also acts as a E3 ubiquitin-protein ligase that mediates monoubiquitination of histone H3. Histone H3 monoubiquitination is required for the joining step of V(D)J recombination. Mediates polyubiquitination of KPNA1.
Function : Core component of the RAG complex, a multiprotein complex that mediates the DNA cleavage phase during V(D)J recombination. V(D)J recombination assembles a diverse repertoire of immunoglobulin and T-cell receptor genes in developing B and T-lymphocytes through rearrangement of different V (variable), in some cases D (diversity), and J (joining) gene segments. DNA cleavage by the RAG complex occurs in 2 steps: a first nick is introduced in the top strand immediately upstream of the heptamer, generating a 3'-hydroxyl group that can attack the phosphodiester bond on the opposite strand in a direct transesterification reaction, thereby creating 4 DNA ends: 2 hairpin coding ends and 2 blunt, 5'-phosphorylated ends. The chromatin structure plays an essential role in the V(D)J recombination reactions and the presence of histone H3 trimethylated at 'Lys-4' (H3K4me3) stimulates both the nicking and haipinning steps. The RAG complex also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. The introduction of DNA breaks by the RAG complex on one immunoglobulin allele induces ATM-dependent repositioning of the other allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. In the RAG complex, RAG2 is not the catalytic component but is required for all known catalytic activities mediated by RAG1. It probably acts as a sensor of chromatin state that recruits the RAG complex to H3K4me3.
Subunit : Component of the RAG complex composed of core components RAG1 and RAG2, and associated component HMGB1 or HMGB2.
Subcellular Location : Nucleus.
DISEASE : Defects in RAG2 are a cause of combined cellular and humoral immune defects with granulomas (CHIDG) [MIM:233650]. CHIDG is an immunodeficiency disease with granulomas in the skin, mucous membranes, and internal organs. Other characteristics include hypogammaglobulinemia, a diminished number of T and B-cells, and sparse thymic tissue on ultrasonography.
Defects in RAG2 are a cause of severe combined
immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-positive (T(-)B(-)NK(+) SCID) [MIM:601457]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Defects in RAG2 are a cause of Omenn syndrome (OS) [MIM:603554]. OS is a severe immunodeficiency characterized by the presence of activated, anergic, oligoclonal T-cells, hypereosinophilia, and high IgE levels.
Similarity : Belongs to the RAG2 family.
Contains 1 PHD-type zinc finger.
Database links : UniProtKB/Swiss-Prot: P55895.1
實驗流程：
全、新、優(yōu)、品、好四大特點：
重組激活基因2蛋白抗體品牌 全：公司提供上萬種產品，涵蓋了生物試劑，elisa試劑盒，標準品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細胞等，基本上各種科研所需產品在我司都能找到。
新：產品更新速度較快，基本上每周都有新產品出現(xiàn)。
優(yōu)：產品質量好，投訴比較少。
好：我公司具有優(yōu)質的技術團隊，產品一旦售出，實驗過程中遇到困難可提供在線技術咨詢。使您使用產品時沒有任何的后顧之憂。
技術外包服務:
★重組激活基因2蛋白抗體品牌 分子生物學：質粒抽提、PCR、Q-PCR、RT-PCR、分子生物學：基因合成、引物合成、基因測序、載體構建等
★蛋白工程：原核、哺乳動物蛋白表達系統(tǒng)等
★病毒包裝：腺病毒、慢病毒等
★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等
★細胞工程：細胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復、克隆形成)、細胞培養(yǎng)、細胞膜制備、穩(wěn)定細胞株構建、細胞RNAi技術等等。
正在熱銷的相關產品：
MAPK4(Mitogen-activated protein kinase 4) 原活化蛋白激酶4抗原Multi-class antibodies規(guī)格： 0.5mg
軸蛋白1Axin protein 1抗體 Anti-Axin1 0.1ml
Rhesus antibody Rh phospho-EGFR (Tyr1068) 磷酸化表皮生長因子受體抗體 規(guī)格 0.1ml
B27添加劑 (原裝) 10ml Gibco
ZNF750 英文名稱： 鋅指蛋白750抗體 0.2ml
DTNBP1 英文名稱： 易感基因抗體 0.1ml
軸蛋白1Axin protein 1抗體 Anti-Axin1 0.1ml
EphA1 R(Ephrin A1 Receptor) EphA1-R受體抗原Multi-class antibodies規(guī)格： 0.5mg
ATP酶通道蛋白抗體 Anti-ATP1b2/Na+K+ ATPase 0.1ml
Rhesus antibody Rh Phospho-EGFR (Tyr1138) 磷酸化表皮生長因子受體抗體 規(guī)格 0.1ml
DMEM/F12(1:1)培養(yǎng)液 250ml 國產
ZNF672 英文名稱： 鋅指蛋白672抗體 0.2ml
DISC1 (CT) 英文名稱： DISC1 C端抗體 0.2ml
ATP酶通道蛋白抗體 Anti-ATP1b2/Na+K+ ATPase 0.1ml
ZEB1 英文名稱： 負調控因子白細胞介素2抗體 0.2ml
DR1 protein 英文名稱： 轉錄下調蛋白1抗體 0.2ml
銜接因子蛋白含pH域磷酸酪氨酸結合域和亮氨酸拉鏈基元1抗體 Anti-APPL1 0.1ml
Anti-CEA/Gold 膠體金離子標記鼠抗人癌胚抗原單克隆抗體(包被)IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh Phospho-eNOS (Thr113) 磷酸化合成酶3抗體(內皮型) 規(guī)格 0.1ml
E2F2 轉錄因子E2F-2抗原Multi-class antibodies規(guī)格： 0.5mg
TNFSF12 Protein Rat 重組大鼠 TNFSF12 蛋白 (Fc 標簽)
DLD-1 人結直腸腺癌上皮細胞
CTSD Others Human 人 Cathepsin D / CTSD 人細胞裂解液 (陽性對照)
CMVECs微內皮細胞 CMVECs micro vascular endothelial cells DMEM+10%FBS
人導管癌細胞;ZR-75-1
人小梁網細胞(HTMC)(5×105) 3T3-L1, 小鼠前脂肪細胞 Mouse
CL-0435SF126(人細胞)5×106cells/瓶×2
HA Others H12N1 甲型 H12N1 (A/mallard duck/Alberta/342/1983) 血凝素 (Hemagglutinin / HA) 人細胞裂解液 (陽性對照)
大鼠視網膜神經節(jié)細胞完全培養(yǎng)基 100mL
HL-7702人正常肝細胞 HL-7702 human normal liver cell 1640+10% FBS
IL1RN Protein Rat 重組大鼠 IL-1RA / IL1RN 蛋白 (Fc 標簽)
NCI-H596(人肺腺鱗癌細胞) 5×106cells/瓶×2 cv-1(非洲綠猴腎細胞)
重組激活基因2蛋白抗體品牌 TNFSF12 Protein Rat 重組大鼠 TNFSF12 蛋白 (Fc 標簽)
DLD-1 人結直腸腺癌上皮細胞
CTSD Others Human 人 Cathepsin D / CTSD 人細胞裂解液 (陽性對照)
CMVECs微內皮細胞 CMVECs micro vascular endothelial cells DMEM+10%FBS
人導管癌細胞;ZR-75-1
人小梁網細胞(HTMC)(5×105) 3T3-L1, 小鼠前脂肪細胞 Mouse
